ArticleScientific reports2025
Activity of lactic acid bacteria against biofilms formed by Staphylococcus aureus strains involved in acute mastitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Probiotics as Sustainable Alternatives to Mitigate Antibiotic Resistance in Bovine Mastitis Management.Probiotics and antimicrobial proteins · 2026Review
- Antibacterial Potential ofFoods (Basel, Switzerland) · 2026Article
- Cell-Free but potent: Antimicrobial potential of Lactobacillus supernatants against multidrug-resistant pathogens.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Staphylococcus aureus is the leading cause of acute mastitis during lactation. This species has a remarkable ability to form biofilms and to develop antibiotic resistance, which hampers the effectiveness of current therapeutic approaches. This study aims to evaluate the therapeutic potential of three lactic acid bacteria (LAB) strains (Limosilactobacillus fermentum I7, Limosilactobacillus reuteri 7SNG3-30 and Ligilactobacillus salivarius 22SNG3-30) to interfere with biofilms formed by two S. aureus strains isolated from milk of women with acute mastitis. Both live LAB cells and their respective cell-free supernatants were able to disrupt the S. aureus biofilm structure and significantly reduce its cellular viability. However, the effectiveness of these treatments was dependent on the S. aureus strain, the LAB strain, and the type of LAB preparation (active culture or cell-free supernatant) involved in each interaction. Overall, our results suggest that the tested LAB strains have the potential to be used either as probiotics or postbiotics complementing the current therapies against acute mastitis and other staphylococcal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.